Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1805 results
April 2015
-
How a love of sport led to a scientific breakthrough
Jeff Weers’ passion inspired a new way of getting inhaled medicine past the body’s natural defenses to reach the lungs.
-
Media ReleaseSandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone® 20mgGlatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis Novartis and Sandoz are driving access to a full…
-
Media ReleaseAlcon receives FDA approval of new multifocal intraocular lens to treat cataract patients in the United StatesUS Food and Drug Administration (FDA) grants approval of the AcrySof® IQ ReSTOR® +2.5 Diopter (D) Intraocular Lens (IOL) for sale in the US Expands Alcon's IOL portfolio for the …
-
Media ReleaseData in The Lancet show Novartis drug Arzerra® plus chlorambucil improved median progression-free survival by 71% in CLL patientsSignificant improvement in PFS seen with Arzerra plus chlorambucil in previously untreated patients with CLL for whom fludarabine-based therapy was inappropriate Chronic lymphocytic…
-
Cancer spies find drug-beating covert cells
-
Media ReleaseGilenya® data at AAN to highlight Novartis leadership in innovation with new MS assessment methods to benefit patients and physiciansNew analysis will confirm high efficacy of Gilenya® in achieving 'no evidence of disease activity' (NEDA4) in previously-treated highly-active RMS patients Separate analyses will show adding…
March 2015
-
Media ReleaseNovartis announces FDA approval for JadenuTM to simplify treatment administration for patients with chronic iron overloadJadenu (deferasirox), a new formulation of Exjade (deferasirox), is the only once-daily oral tablet for iron chelation Jadenu, taken with or without food, simplifies daily treatment…
-
New recruit has big dreams for cancer immunotherapy
Immunotherapy for cancer is on the brink of breakthroughs. Learn how NIBR have high expectations for this medical science.
-
Media ReleaseNovartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research groupCollaboration with Aduro is focused on discovery and development of next generation cancer immunotherapies targeting the STING signaling pathway Addition of STING agonists further enhances…
-
Media ReleaseNovartis' Cosentyx(TM) two-year data shows sustained effect and favorable safety profile in psoriasis patientsAfter two full years of therapy with Cosentyx 300 mg, almost 9 out of 10 psoriasis patients sustained their PASI 75 response[1] New data at AAD shows 7 out of 10 psoriasis patients, who…
-
Media ReleaseNew Novartis data shows Cosentyx(TM) is significantly superior to Stelara® and clears skin (PASI 90) in nearly 80% of psoriasis patientsCLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx(TM) compared to Stelara® at Week 16[1] Cosentyx showed greater improvements…
-
Psoriasis: The story of a hidden condition
More than 125 million people worldwide live with psoriasis, a chronic autoimmune disease that causes red, scaly patches to appear on the skin.
Pagination
- ‹ Previous page
- 1
- …
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- …
- 151
- › Next page